| cardiovascular prevention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CAPTIVATE, 2009 | vs placebo | | | | | ACTIVATE, 2006 | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| CAPTIVATE, 2009 | pactimibe 100mg daily (n=448) vs. placebo (n=444) | patients with familial hypercholesterolemia and carotid atherosclerosis | double blind Parallel groups Sample size: 448/444 Primary endpoint: maximum CIM at 12 months FU duration: 15 months (mean) | | ACTIVATE, 2006 | pactimibe 100 mg daily (n=266) vs. placebo (n=268) | patients with angiographicallydocumented coronary disease | double blind Parallel groups Sample size: 266/268 Primary endpoint: atheroma volume FU duration: 18 months |
|
| familial hypercholesterolemia | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CAPTIVATE, 2009 | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| CAPTIVATE, 2009 | pactimibe 100mg daily (n=448) vs. placebo (n=444) | patients with familial hypercholesterolemia and carotid atherosclerosis | double blind Parallel groups Sample size: 448/444 Primary endpoint: maximum CIM at 12 months FU duration: 15 months (mean) |
|
